Welcome to our dedicated page for PRF Technologies Ltd. news (Ticker: PRFX), a resource for investors and traders seeking the latest updates and insights on PRF Technologies Ltd. stock.
PainReform Ltd. (Nasdaq: PRFX) generates news across two main areas: specialty pharmaceutical development for post-surgical pain and ophthalmology, and AI-driven solar and energy analytics through its DeepSolar platform. Company updates often highlight progress in extended-release drug-delivery technologies and in advanced digital tools for managing solar assets.
On the pharmaceutical side, news items cover developments in PRF-110, PainReform’s oil-based ropivacaine formulation for localized post-operative analgesia, and the OcuRing™-K program acquired through its majority investment in LayerBio. Releases describe preclinical and clinical milestones for OcuRing-K, including Phase I safety data in cataract surgery patients and R&D assessments showing that the sustained-release matrix can incorporate multiple drug entities such as corticosteroids and NSAIDs. These updates provide insight into how the company is pursuing dropless, sustained-release approaches to post-cataract pain and inflammation management.
In parallel, DeepSolar-related news focuses on AI-based solar analytics and energy optimization. Coverage includes the development of DeepSolar Predict, an AI forecasting module for photovoltaic systems advanced within the NVIDIA Connect program, the launch of Smart TDD for solar technical due diligence, and progress on an automated reporting engine that consolidates operational data into tailored performance reports. PainReform has also reported on pilot and commercial engagements for DeepSolar, such as a 92MW project with Econergy Renewable Energy.
Investors and observers can use this news feed to follow regulatory and clinical steps for PainReform’s pharmaceutical candidates, as well as product launches, technology collaborations, and commercial milestones in its DeepSolar business. Regular updates provide context on how the company advances its dual focus on non-opiate pain management and renewable-energy analytics.
PainReform Ltd. (PRFX) has made significant progress in developing its lead product, PRF-110, designed for post-surgical pain relief. The company has successfully completed tech transfer for manufacturing clinical batches and is on track to start Phase 3 clinical trials in bunionectomy by Q4 2022. Financially, PainReform reported a net loss of $3.5 million for the first half of 2022, an improvement from a $3.7 million loss in 2021. The company maintains a strong balance sheet with $13.8 million cash on hand, sufficient to support ongoing activities and trials.
PainReform (Nasdaq: PRFX) has received a Nasdaq Listing Qualifications notice indicating non-compliance with the minimum bid price requirement of $1.00 per share. The company has a 180-day grace period until February 6, 2023, to regain compliance by maintaining a closing bid price of at least $1 for ten consecutive business days. If compliance is not achieved, PainReform may be subject to delisting. Despite this, the current trading of its shares will continue on the Nasdaq Capital Market during the grace period.
PainReform (Nasdaq: PRFX) announced successful batch manufacturing of PRF-110 and progress towards Phase 3 clinical trials expected in H2 2022. CEO Ilan Hadar confirmed that FDA approval for the 505(b)(2) pathway sets the stage for efficient trial execution. The company has $15.4 million in cash and no debt, ensuring capital availability for key milestones. Q1 2022 reported R&D expenses decreased to $680,000, and net loss decreased to $1.694 million, reflecting cost management. PainReform focuses on reformulating established therapeutics for enhanced surgical pain relief.
PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company, announced that CEO Ilan Hadar will present at the Noble Capital Markets’ Eighteenth Annual Investor Conference on April 20-21, 2022, in Hollywood, Florida. Hadar's presentation is scheduled for April 20 at 12:00 pm ET in Seminole Ballroom C, with a breakout session at 4:00 pm ET at Table 9. A video webcast of the presentation will be available the following day on the Company's website and other platforms, archived for 90 days.
PainReform Ltd. (Nasdaq: PRFX) announced its participation in the 2022 Virtual Growth Conference hosted by Maxim Group LLC and M-Vest, scheduled for March 28-30, 2022, from 9:00 a.m. to 5:00 p.m. EDT. The conference will include various discussions and presentations, featuring a corporate update by CEO Ilan Hadar. To attend, individuals must register as M-Vest members. PainReform focuses on reformulating established therapeutics, with its lead product PRF-110 aimed at providing extended post-operative pain relief through a unique drug-delivery system.
PainReform Ltd. (Nasdaq: PRFX) provided a business update for 2021, revealing plans to start a Phase 3 trial of PRF-110 for bunionectomy in H2 2022. The company has $16.6 million in cash, a positive working capital of $18.3 million, and no debt. R&D expenses surged to $2.9 million from $0.4 million in 2020, while the net loss increased to $7.2 million. PainReform's lead product, PRF-110, aims to meet the $35 billion post-operative pain management market, potentially reducing opioid use. Key developments are anticipated in 2022 to enhance shareholder value.
TEL AVIV, Israel, Dec. 14, 2021 – PainReform Ltd. (Nasdaq: PRFX) announced that CEO Ilan Hadar will participate in the Benzinga All Access event on December 16, 2021, at 10:00 A.M. ET. The event features a live interview with Spencer Israel, Executive Producer of Benzinga TV. Investors can watch the event here. PainReform, focused on reformulating established therapeutics, aims to provide extended post-operative pain relief with its product PRF-110.
PainReform (Nasdaq: PRFX) has reported progress towards commencing Phase 3 clinical trials for PRF-110, its lead product aimed at post-operative pain relief, using ropivacaine. The company has selected Pharmaceutics International, Inc. as its U.S. manufacturer for clinical batches. They expect to start the first trial in bunionectomy by late 2022. Despite a net loss of $5.5 million for the first nine months of 2021, PainReform maintains a healthy cash balance of $18.4 million, providing a runway for important milestones ahead.
PainReform Ltd. (Nasdaq: PRFX) announced that CEO Ilan Hadar will present at the Dawson James Securities Small Cap Growth Conference on October 21, 2021, at 3:15 PM ET in Jupiter, Florida. This conference will feature one-on-one meetings with qualified investors. The live webcast and recorded presentation will be accessible on PainReform's investor relations website. PainReform specializes in reformulating therapeutics, focusing on PRF-110, which targets post-operative pain relief through an innovative drug-delivery system.
PainReform Ltd. (NASDAQ: PRFX) announced a shift of manufacturing operations for its lead product, PRF-110, to a U.S.-based Contract Development and Manufacturing Organization to enhance quality and efficiency. This decision aims to resolve previous manufacturing delays, with plans to initiate Phase 3 clinical trials by Q1 2022. As of June 30, 2021, PainReform reported $17.8 million in cash, which increased to over $19 million following recent warrant exercises. The company also reported a net loss of $3.7 million for the first half of 2021, up from $2.0 million a year earlier.